The future of inflammatory bowel disease management

TY - JOUR

T1 - The future of inflammatory bowel disease management

AU - Ciorba, Matthew A.

N1 - Funding Information: M.A.C. has received support from the NIDDK P30 DK052574, T32 DK007130, R01 DK109384, R56 AI167285, The Lawrence C. Pakula MD IBD Innovation Fund at Washington University and investigator-initiated sponsored research agreements from Pfizer (#61798927) and Janssen (NOPRODIBD0001). Funding Information: M.A.C. has received grants from Pfizer, Janssen, BMS, Takeda and AbbVie. M.A.C. has provided consulting services to Takeda, Pfizer, Janssen, BMS and Aclaris.

PY - 2022/7/1

Y1 - 2022/7/1

UR - https://www.scopus.com/pages/publications/85133144387

U2 - 10.1097/MOG.0000000000000856

DO - 10.1097/MOG.0000000000000856

M3 - Editorial

C2 - 35762690

AN - SCOPUS:85133144387

SN - 0267-1379

VL - 38

SP - 319

EP - 320

JO - Current opinion in gastroenterology

JF - Current opinion in gastroenterology

IS - 4

ER -